Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Gorf79on Aug 12, 2022 6:32pm
231 Views
Post# 34893085

RE:EDEN could be significant in expanding the label

RE:EDEN could be significant in expanding the labelSpectral certainly likes their Biblical references.

This study will be very significant I suspect. It may lead to an earlier ending of the trial as well.

As always, and as MM said, the share price is whatever they want it to be and today they decided that a 15% haircut after the Veteran's Administration deal was an appropriate close. What else would a 50 cent, 32 person company do after inking a major dialysis deal within the largest healthcare network in the United States?

Of course it would lose 15%... maybe more.

Meaningless! It is and always has been meaningless.

The company has made infinite leaps forward in the last several weeks and is closer than ever to where the 90% of insider shares want it to be.

If people are jittery they should sell. 
<< Previous
Bullboard Posts
Next >>